Theranica to Present Real-World Evidence on Nerivio for migraine Treatment

published: 2025/08/08 12:38:02

Theranica, a digital therapeutics company, is set to present three real-world evidence (RWE) studies at the American Headache Society (AHS) Scientific Meeting, demonstrating the effectiveness of its Nerivio Remote Electrical neuromodulation (REN) wearable device in treating migraine. The presentations will highlight data supporting the device’s impact on migraine treatment in real-world clinical settings.

Understanding Nerivio and Remote electrical Neuromodulation (REN)

Nerivio is a non-invasive, drug-free wearable device designed to treat acute migraine attacks. It utilizes REN technology, which delivers electrical stimulation to the upper arm to modulate pain signals and provide relief. REN works by activating the body’s natural pain relief mechanisms, offering an option to traditional migraine treatments like medication. Learn more about the science behind Nerivio.

Key Findings from the Real-World Evidence Studies

The three studies to be presented at the AHS meeting provide further evidence of Nerivio’s benefits in a diverse patient population. While specific details of the studies were not available in the source, the declaration indicates a focus on real-world application and impact. Real-world evidence is especially valuable as it reflects how a treatment performs outside of controlled clinical trials,offering insights into its effectiveness in everyday clinical practice.

Study Focus Areas (Based on Announcement)

• Efficacy in Routine Clinical Practice: Data demonstrating how Nerivio performs when used by patients and managed by healthcare providers in typical clinical settings.
• Patient-Reported Outcomes: Insights into how patients experiance relief from migraine symptoms using Nerivio, including improvements in pain levels, functionality, and quality of life.
• impact on Medication Usage: analysis of whether Nerivio use leads to a reduction in the need for acute migraine medications.

American Headache Society (AHS) scientific meeting

The American headache Society Scientific Meeting is a leading conference for healthcare professionals specializing in headache and migraine management. It provides a platform for researchers and clinicians to share the latest advancements in the field. Visit the AHS website for more data about the meeting.

Key Takeaways

• Theranica is presenting three RWE studies on Nerivio at the AHS Scientific Meeting.
• The studies focus on the real-world impact of Nerivio on migraine treatment.
• Nerivio utilizes REN technology, a non-invasive, drug-free approach to migraine relief.
• The AHS meeting is a key event for headache and migraine specialists.

looking Ahead

The presentation of these real-world evidence studies at the AHS meeting represents a critically importent step in validating the effectiveness of Nerivio as a migraine treatment option. Continued research and data collection will further refine our understanding of how Nerivio can best be utilized to improve the lives of individuals living with migraine. Theranica’s commitment to providing innovative digital therapeutics offers hope for more effective and accessible migraine management in the future.

Editor’s Note: Graphics in this video were provided by Theranica.